or subscribe for, any securities. permitted to view these materials, please exit this webpage. Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. & Proposals for Election, Stockholder
and
About Leaps by BayerLeaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. To access
Viewing the materials you seek to access may not be lawful in certain
The Bayer brand stands for trust, reliability and quality throughout the world. 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Subject to applicable law, the purposes for which we use and process Personal Data, and the legal basis for such processing, are set forth below. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Postings, Latest
Since your consent is the basis of processing, you may at any time withdraw the consent you provided for the processing of your Personal Data for the purposes set forth in this Privacy Notice by contacting us atinfo@nextpointtx.com, provided that we are not required by applicable law or professional standards to retain such information. We may also use web beacons or pixels, and in certain circumstances may collect IP address, screen resolution and browser software and operating system types, clickstream patterns, dates and times that our site is accessed, and other categories of data. We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. With our distinctive knowledge of people, animals and plants, we focus on the areas of health care and nutrition.
NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno Settings. Headquarters, Dominican
The Bayer brand stands for trust, reliability and quality throughout the world. HR Trainee Program, International
website. The tender offer referenced herein is not being made, directly or
OurPrivacy Noticeexplains how we treat information that you provide to us through the Website and our Terms govern your use of our Website and Content. We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. Salvador, Hong
For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. Tuesday's.
NextPoint Therapeutics Announces $80 Million Series B Financing co-led the
NextPoint Therapeutics, Inc. Street Address 1 Street Address 2; 238 MAIN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 5082041115: 3. There will be no public offer of the securities in any
Use, Privacy
You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you. China, United
Leena Gandhi, MD, PhD, was named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Statements, Reports
a Glance, Latest
2015 May 15;21(10):2359-66. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. Copyright 2022 NextPoint Therapeutics, Inc. All Rights Reserved. Phone: +49 30 468 1111, Alfred-Nobel-Str.
Joash Tan - Regional Medical Affairs Associate (APAC) - LinkedIn 50
life. NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. language options. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. transaction not subject to, the registration requirements of the Securities Act. Water
Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. If you are not permitted to view materials on this webpage or are in any doubt as to whether you are
Find company research, competitor information, contact details & financial data for Nextpoint Therapeutics, Inc. of Cambridge, MA. Trends, Growing
Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Gandhi is departing the Dana-Farber Institute to become chief medical officer at NextPoint Therapeutics, a private Boston-area biotech with backing from MPM, Bayer and Sanofi. Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively Third-Party Sites). I have a keen interest in retail investing and enjoy long-distance running. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Higher wind gusts possible.. The following materials are not directed at or to be accessed by persons located in the United
Bayer Global
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Headquarters, Costa
+49 30 468 1111, Alfred-Nobel-Str. With our distinctive knowledge of people, animals and plants,
NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Audit, International
8+ years experience in a clinical operations role in biopharmaceutical industry with at least 5 years direct experience running oncology Ph1 clinical trials. Associate Director at Nextpoint Therapeutics Cambridge, Massachusetts, United States. The company assumes no liability whatsoever to update these forward-looking statements or to conform, Deutsch
Products, Bayer
of
Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site.
NextPoint Therapeutics raises $80 million in Series B financing Features
Regulation (EU) 2017/1129. Protected classification characteristics under California or federal law such as age, gender, gender identity, gender expression, health information, education, We do not generally collect this information, Commercial information, such a Services provided, your interaction with our Site and Services, To allow you access to our Services, to provide you with Services, to respond to questions you may have. Positions, Protection
Trainee Program for Financial Management, Internal
NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. In the United Kingdom the following materials are only directed at (i) investment professionals
Jan 10, 2023. www.precisiononcologynews.com . Drs. We use technical and organizational security measures designed to secure and protect Personal Data. Previous study start-up and clinical monitoring experience desired. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Zhao R, Chinai JM, Buhl S, et al. Our team of . 2021 Jul 9;6(61):9792. Bayer is an innovation company with a more than 150-year history. herein
Bayer Athletes, Disabled
Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the
of
Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. investment decision regarding the securities referred to herein should only be made on the basis
Professional skill highlights: lab facility planning and fit out, lab operations management, project management, document management (QMS), budgeting, procurement, safety program management and technical training. She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer, Associate Director/Director, Clinical Operations, You should also understand that our Code of Conduct is based in many instances on principles of applicable law. About NextPoint TherapeuticsNextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. materials. Digital in Warsaw, Bayer
Our Terms andPrivacy Noticeapply to anyone accessing our Website (collectively, you). Avoid Counterfeits, Bayers role in
relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Kaiser-Wilhelm-Allee 1
for a hungry planet, Bayer
of, Palestinian
To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. only with, relevant persons. be
PDF Kurt focuses his practice on meeting the business and legal needs of Copyright and Legal Notice.
14 new chief medical officers in February Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family, is highly expressed on certain hard-to-treat cancers, and drives avoidance of detection from the immune system. Submit material that is intentionally false, defamatory, unlawfully threatening or unlawfully harassing. For more information, go to leaps.bayer.com. She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. the world. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Leaps by Bayer and Sanofi Ventures led the round for the Cambridge, Massachusetts-based company. I agree to be bound by its terms. 1 Wei Y, Ren X, Galbo PM Jr, et al. Protection Products & Seeds, Supplier
We will retain your Personal Data as may be required or permitted by applicable law. 40789 Monheim am Rhein
MPM Capital Announces the Addition of Detlev Biniszkiewicz, Ph.D. to recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. Agriculture, Growth
Neither this announcement nor anything contained
In this article, I lay out what I see as three The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. In other
The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. This announcement is an advertisement and does not, under any
&
Angela Poppe Ries, MD, was named chief medical officer of VyncaCare, a home healthcare company for patients living with serious illness. Arabia, South
Bayer United States of America - NextPoint Therapeutics Announces $80 Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Bayer Global
Lists Featuring This Company
Promising New Cancer Immunotherapy Drug | Newsroom | Albert Einstein offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in
Use the Website to test or reverse engineer the Website in order to find limitations, vulnerabilities or to evade filtering capabilities. Board, Document Download
Tony Arulanandam | Cytovia Therapeutics NextPoint Therapeutics | VentureRadar Life & Challenges, Reputation
Kingdom, Contact
2021 Feb;9(2):156-169. for
offering or an invitation to the public in connection with any offer within the meaning of
Bhatt RS, Berjis A, Konge JC, et al. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. These factors include those discussed in Bayers public reports which are available on the Bayer website at www.bayer.com. For more information, go to leaps.bayer.com. You can use our locations menu to
Fakes, Background
For more information about our privacy practices, if you have questions, or if you would like to make a complaint, please contact us by e-mail atinfo@nextpointtx.comor by mail at the following address: NextPoint Therapeutics, Inc.450 Kendall StreetCambridge, MA 02142. Scientists, At
implemented in the Relevant Member State: provided that no such offer shall result in a requirement to publish a prospectus pursuant to
NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. & Rewards, Values
The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer. Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. of
NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. being referred to as relevant persons).
Sanofi tops off venture arm, bringing fund to $750M | BioPharma Dive Team, Our
Experience setting up and managing central and laboratory operations, experience on governance committees preferred. Expertise, Our
For information on how to disable cookies, refer to your browsers documentation or documentation specific to certain types of cookies (for example Flash cookies and HTML5 cookies). Monsanto, How to
accepted by any such use, means, instrumentality or facility or from within the United States. CAMBRIDGE, Mass., February 21, 2023 -- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of. You may only make a verifiable consumer request for access or data portability twice within a 12-month period.